ASYMCHEM
Asymchem Laboratories (Tianjin) Co., Ltd. (Stock Code 002821.SZ/6821.HK) announced today that it will operate the former Pfizer U.K. small molecule API pilot plant and part of the development laboratories through a new lease agreement between Asymchem and Discovery Park, establishing Asymchem’s first manufacturing footprint in Europe. Asymchem will continue to operate the site in Sandwich, Kent, as a clinical small molecule development and manufacturing facility to meet global client demands for pharma services and supply.
The development laboratories are expected to begin operation in June 2024, followed by the API pilot plant in August. The site is expected to employ approximately 100 individuals by the end of 2024, including many staff previously employed by Pfizer. Planned additions for the site include capabilities for the manufacture of peptides and oligonucleotides, as well as sustainability capabilities utilizing continuous flow and biocatalysis.
“We are excited to become a part of the European pharma manufacturing community,” said Chairman and CEO of Asymchem Group, Dr. Hao Hong. “Meeting the needs of our clients in bringing manufacturing into the Western market will continue to be part of our long-term strategy to meet overall global business demands.”
Mayer Schreiber, CEO of Discovery Park, said: “We are delighted to welcome Asymchem to Discovery Park this summer. The organisation has selected Discovery Park as their European base and home to their first manufacturing facility in Europe, bringing new jobs and safeguarding scientific talent. Asymchem joins a burgeoning community of over 160 companies in a designated Life Sciences Opportunity Zone, representing an incredible talent pool which contributes significantly to the U.K. life sciences economy.”
About Asymchem
Asymchem is a global technology-driven contract development and manufacturing organization (CDMO) providing services to the pharmaceutical industry. Founded in 1997, Asymchem employs over 9300 personnel world-wide, with R&D and manufacturing operations in China and the U.S.
Forward-Looking Statements
This press release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to the Company, are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections, and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties, and other factors, some of which are beyond the Company’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of a number of factors, including, without limitation, future changes or developments in our business, the Company’s competitive environment and political, economic, legal and social conditions.
The Company, its directors and the employees assume (a) no obligation to correct or update the forward-looking statements contained in this announcement; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.
About Discovery Park
Discovery Park is a thriving UK life science community for visionary entrepreneurs and leaders. Within easy reach of London, Discovery Park spearheads Kent’s flourishing science and technology cluster.
Discovery Park offers state-of-the-art labs, modern offices and manufacturing facilities, unrivalled flexibility and comprehensive support including access to finance and a strong local talent pool.
Discovery Park has been a major centre for life science for nearly 70 years and is home to 160+ companies across a growing tenant community of dynamic start-ups through to global corporations. This includes Algaecytes, Canterbury Christ Church University, Concept Life Sciences, eXroid, Genea Biomedx, LGC, Pfizer, Psyros Diagnostics, Salvensis, Viatris, VisusNano and Wren Healthcare.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240521088343/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ares Management and Slate Asset Management to Acquire Polish Real Estate Portfolio Valued at Over €300 Million From Trei Real Estate28.10.2025 09:15:00 CET | Press release
Ares Management Corporation (“Ares”) (NYSE: ARES), a leading global alternative investment manager, and Slate Asset Management (“Slate”), a global investor and manager focused on essential real estate and infrastructure, today announced that a joint venture between Ares Real Estate funds (“Ares Real Estate”) and Slate has agreed to acquire a portfolio of 36 properties in Poland (the “Portfolio”) from Trei Real Estate, an internationally active developer and asset manager. The Portfolio is valued at over €300 million. The Portfolio comprises 36 recently developed and fully occupied convenience-led retail parks strategically located across major Polish metropolitan areas near large catchment populations. The assets are inflation-protected through CPI-linked lease agreements underpinned by tenants with strong covenants. Most of the Portfolio’s income is derived from large regional retailers and essential goods providers, including grocers and pharmacies. “This transaction underlines our c
SK pharmteco Achieves Highest-Level My Green Lab Certifications Across Europe and Asia28.10.2025 09:00:00 CET | Press release
Green certification is the top tier of the globally recognized My Green Lab program for laboratory sustainability excellence SK pharmteco, a global contract development and manufacturing organization (CDMO), today announced a significant milestone in its commitment to environmental sustainability by earning four My Green Lab certifications, including two at the program’s highest level, Green. The remaining two labs earned Gold certification, reflecting advanced sustainability performance and progression toward full Green maturity. The certified facilities are Small Molecule Europe (Swords, Ireland) and Small Molecule Asia (Daejeon, South Korea), and the certifications cover the areas of Quality Control, Process Research & Development, and Analytical Research & Development. My Green Lab certification is widely regarded as the global standard for laboratory sustainability, recognized by the United Nations Race to Zero campaign for its rigor in advancing credible decarbonization. Green ce
Kemwell Biopharma Facility in Bengaluru Successfully Completes U.S. FDA Inspection for Commercial Drug-Product Manufacturing28.10.2025 07:00:00 CET | Press release
Milestone expands India’s role in global biologics manufacturing; collaboration with Cipla underscores commitment to quality and reliability Kemwell Biopharma Pvt Ltd (“Kemwell”), a leading global biologics Contract Development and Manufacturing Organization (CDMO), announced today that its drug-product manufacturing facility in Bengaluru has successfully completed a U.S. Food and Drug Administration (FDA) pre-approval inspection (PAI) and is now cleared for the commercial manufacturing and testing of injectable products destined for the U.S. market. This milestone marks the approval of the first product to get U.S. FDA clearance for commercial supply from Kemwell’s Bengaluru drug-product facility since the site became a dedicated biologics campus eight years ago. It demonstrates the company’s ability to meet stringent current Good Manufacturing Practice (cGMP) and aseptic drug-product manufacturing standards. “Achieving FDA clearance for commercial manufacturing from our Bengaluru sit
Uzbekistan's National Payment System HUMO and Ant International’s Alipay+ Partner to Facilitate Cross-Border QR Payments28.10.2025 06:55:00 CET | Press release
HUMO will be the 10th national QR network to partner with Alipay+, enabling its network of Uzbek digital payment apps to make cross-border QR payments across Alipay+’s global merchant ecosystem.The Octomobile app by Octobank, supported by HUMO, will be the first Uzbek e-wallet to be integrated with Alipay+, with more Uzbek e-wallets expected to join by the end of the year.Alipay+ now partners with 40 e-wallets and bank apps and 10 national QR payment schemes and payment systems worldwide, connecting over 100 million merchants to 1.8 billion consumers accounts. Alipay+, Ant International’s global wallet gateway, and HUMO, the national payment system in Uzbekistan, announced the partnership in Beijing to facilitate inbound and outbound cross-border QR payments. The Octomobile app by Octobank will be the first Uzbek e-wallet integrated with Alipay+, with more HUMO-connected local e-wallets and bank apps expected to join by the end of the year. This press release features multimedia. View
e.l.f. Beauty Releases FY2025 Impact Report with Emphasis on ‘the Every’28.10.2025 05:01:00 CET | Press release
Bold new campaign encourages the community to “give an e.l.f.” and join the company in making the world a better place for every eye, lip and face e.l.f. Beauty (NYSE: ELF), a purpose-led, results-driven company on a mission to make the best of beauty accessible to every eye, lip and face, today released its fourth annual Impact Report. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251027352775/en/ e.l.f. Beauty releases 4th annual Impact Report, emphasizing it’s evolved purpose statement: to make the world a better place for every eye, lip and face. The digital-first report is built around the theme of “the every”— a reflection of e.l.f.’s commitment to be a bold disruptor with a kind heart. To amplify the message behind the Impact Report, e.l.f. also launched a bold, international consumer campaign: “Give an e.l.f.” The campaign features voices of kindred spirits and encourages the community to fuel their own sense of pur
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom